Johnson & Johnson (J&J) has been granted patent for its anti retroviral drug (ARV) Etravirine in India which is used in combination with anti-HIV drugs to treat patients who are usually resistant to multiple HIV drug medication.

Johnson & Johnson (J&J) has been granted patent for its anti retroviral drug (ARV) Etravirine in India. It is the second ARV drug being approved a patent in India after Pfizer got the approval for Maravoric last year. J&J received the patent recently. It is to be used in combination with anti-HIV drugs to treat patients who are usually resistant to multiple HIV drug medication. It is marketed are the brand name of Intelence.

It is opined that the drug could be helpful in prolonging the use of a particular drug in patients. However, as it is a new drug, its efficacy and relevance in developing countries like India remain yet to be tested.